日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study

一项针对不适合接受经导管动脉化疗栓塞术(TACE)且肿瘤负荷超过“Up-To-7”标准的中晚期肝细胞癌患者的阿特珠单抗联合贝伐珠单抗治疗的II期研究的主要分析:REPLACEMENT研究

Kudo, Masatoshi; Ueshima, Kazuomi; Tsuchiya, Kaoru; Yamashita, Tatsuya; Shimose, Shigeo; Numata, Kazushi; Kodama, Yuzo; Itoh, Shinji; Tanaka, Yasuhito; Kuroda, Hidekatsu; Aikata, Hiroshi; Hiraoka, Atsushi; Moriguchi, Michihisa; Tateishi, Ryosuke; Ogasawara, Sadahisa; Yamamoto, Kouji; Ikeda, Masafumi

Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150

治疗深度和持续时间与不可切除肝细胞癌患者的生存率相关:IMbrave150 的探索性分析

Kudo, Masatoshi; Yamashita, Tatsuya; Finn, Richard S; Galle, Peter R; Ducreux, Michel; Cheng, Ann-Lii; Tsuchiya, Kaoru; Sakamoto, Naoya; Hige, Shuhei; Take, Ryosuke; Yamada, Kyoko; Nakagawa, Yuki; Takahashi, Hayato; Ikeda, Masafumi

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

血清 FGF21 作为预测 HCC 对阿特珠单抗和贝伐珠单抗反应的指标

Kohya Risako, Suda Goki, Ohara Masatsugu, Hosoda Shunichi, Sho Takuya, Chuma Makoto, Komori Atsumasa, Kugiyama Yuki, Yasui Yutaka, Tsuchiya Kaoru, Kurosaki Masayuki, Tani Joji, Kaneko Shun, Nakagawa Mina, Asahina Yasuhiro, Maekawa Shinya, Enomoto Nobuyuki, Yamamoto Yoshiya, Baba Masaru, Yamada Ren, Sasaki Takashi, Yoda Tomoka, Yoshida Sonoe, Fu Qingjie, Yang Zijian, Maehara Osamu, Ohnishi Shunsuke, Tokuchi Yoshimasa, Kitagataya Takashi, Kawagishi Naoki, Nakai Masato, Natsuizaka Mitsuteru, Ogawa Koji, Sakamoto Naoya

Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study

不可切除的早期至中期肝细胞癌根治性转化治疗后阿特珠单抗联合贝伐珠单抗停药标准的提议:一项多中心概念验证研究

Aoki, Tomoko; Kudo, Masatoshi; Nishida, Naoshi; Ueshima, Kazuomi; Tsuchiya, Kaoru; Tada, Toshifumi; Morita, Masahiro; Chishina, Hirokazu; Takita, Masahiro; Hagiwara, Satoru; Ida, Hiroshi; Minami, Yasunori; Kuroda, Hidekatsu; Nakamura, Noriaki; Hiraoka, Atsushi; Tomonari, Tetsu; Tani, Joji; Naganuma, Atsushi; Kakizaki, Satoru; Ogawa, Chikara; Hatanaka, Takeshi; Ishikawa, Toru; Kawata, Kazuhito; Takebe, Atsushi; Matsumoto, Ippei; Hidaka, Masaaki; Kurosaki, Masayuki; Kumada, Takashi; Izumi, Namiki

Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B)

老年不可切除胆道癌患者的联合化疗:一项采用倾向评分匹配分析的前瞻性观察研究(JON2104-B)

Kobayashi, Satoshi; Nakachi, Kohei; Yamamoto, Kouji; Ueno, Makoto; Maruki, Yuta; Ikezawa, Kenji; Terashima, Takeshi; Shimizu, Satoshi; Oshima, Kotoe; Tsuji, Kunihiro; Masaki, Yoshiharu; Tsumura, Hidetaka; Shibuki, Taro; Ozaka, Masato; Okano, Naohiro; Okamura, Yukiyasu; Umemoto, Kumiko; Satoh, Tatsunori; Kojima, Yasushi; Shioji, Kazuhiko; Nebiki, Hiroko; Doi, Toshifumi; Naganuma, Atsushi; Kataoka, Shigeki; Kita, Emiri; Asama, Hiroyuki; Tsuchiya, Kaoru; Unno, Michiaki; Ashida, Reiko; Matsumoto, Kazuyuki; Ohno, Izumi; Itoi, Takao; Negoro, Yuji; Sakamoto, Yasunari; Arima, Shiho; Asagi, Akinori; Okuyama, Hiroyuki; Komatsu, Yoshito; Kobayashi, Noritoshi; Nagano, Hiroaki; Furuse, Junji

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿特珠单抗联合贝伐珠单抗治疗不适合经TACE治疗且超出Up-To-7标准的中晚期肝细胞癌:REPLACEMENT研究的最终分析

Ueshima, Kazuomi; Tsuchiya, Kaoru; Yamashita, Tatsuya; Shimose, Shigeo; Numata, Kazushi; Kodama, Yuzo; Itoh, Shinji; Tanaka, Yasuhito; Kuroda, Hidekatsu; Ohkawa, Kazuyoshi; Kuzuya, Teiji; Ikeda, Masafumi; Kooka, Youhei; Aikata, Hiroshi; Hiraoka, Atsushi; Moriguchi, Michihisa; Tateishi, Ryosuke; Ogasawara, Sadahisa; Yamamoto, Kouji; Kudo, Masatoshi

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma

IMPACT 研究方案:一项随机、多中心、3 期研究,旨在评估免疫疗法(阿特珠单抗)联合抗 VEGF 疗法(贝伐珠单抗)以及经导管动脉化疗栓塞术治疗不可切除肝细胞癌的疗效。

Kodama, Yoshihisa; Ueshima, Kazuomi; Moriguchi, Michihisa; Inaba, Yoshitaka; Yamashita, Tatsuya; Iwamoto, Hideki; Ueno, Makoto; Ogasawara, Sadahisa; Kuzuya, Teiji; Kodama, Takahiro; Sato, Yozo; Tada, Toshifumi; Tsuchiya, Kaoru; Nishiofuku, Hideyuki; Yamakado, Koichiro; Sone, Miyuki; Ikeda, Masafumi; Takehara, Tetsuo; Hamano, Tetsutaro; Kudo, Masatoshi

Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds

FIB-4 指数和 FIB-3 指数对慢性肝病晚期纤维化的诊断准确性及年龄特异性阈值

Kimura, Shohei; Tamaki, Nobuharu; Higuchi, Mayu; Shima, Takuya; Taguchi, Mina; Yamazaki, Yudai; Seike, Risa; Uchihara, Naoki; Tanaka, Yuki; Kobayashi, Ryohei; Yagita, Junko; Kasano, Yuka; Komiyama, Yasuyuki; Takaura, Kenta; Takada, Hitomi; Tanaka, Shohei; Maeyashiki, Chiaki; Yasui, Yutaka; Nakanishi, Hiroyuki; Tsuchiya, Kaoru; Izumi, Namiki; Kurosaki, Masayuki

Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older

射频消融术治疗80岁及以上肝细胞癌患者的临床疗效

Takaura, Kenta; Tsuchiya, Kaoru; Taguchi, Mina; Tokunaga, Yuzuki; Uchihara, Naoki; Kimura, Shohei; Tanaka, Yuuki; Yagita, Junko; Miyamoto, Haruka; Keitoku, Taisei; Okada, Risa; Higuchi, Mayu; Tanaka, Shohei; Maeyashiki, Chiaki; Tamaki, Nobuharu; Yasui, Yutaka; Takahashi, Yuka; Nakanishi, Hiroyuki; Izumi, Namiki; Kurosaki, Masayuki

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy

乐伐替尼治疗前蛋白尿对阿特珠单抗联合贝伐珠单抗治疗反应的影响

Ochi, Hironori; Kurosaki, Masayuki; Tanaka, Takaaki; Tamaki, Nobuharu; Tsuchiya, Kaoru; Yasui, Yutaka; Marusawa, Hiroyuki; Tada, Toshifumi; Nakamura, Shinichiro; Akahane, Takehiro; Okamoto, Eisuke; Kobashi, Haruhiko; Arai, Hirotaka; Nonogi, Michiko; Izumi, Namiki